
peterschreiber.media
- BMO Capital Markets downgraded Exelixis (NASDAQ:Excel) to outperform the market as it sees limited upside for the stock in 2025.
- The investment firm said it sees a balanced risk/reward for the upcoming reading of zanzalintinib in colorectal cancer, or